Eurasian Journal of Critical Care

Yazarlar: ["Ali SARIDAŞ"]

Konular:-

DOI:10.55994/ejcc.1112050

Anahtar Kelimeler:SARS-CoV-2,COVID-19,Molnupiravir

Özet: The novel coronavirus disease 2019 (COVID-19) emerged in China in late December 2019 and quickly spread to many countries around the world. Antiviral drugs are candidate treatments for the treatment of COVID-19. Molnupiravir, the first oral antiviral drug, is a drug with anti-RNA polymerase activity and is currently being used for the treatment of COVID-19 patients. In this review, we aimed to discuss the mechanism of action, safety, efficacy and clinical studies of molnupiravir in the treatment of patients with COVID-19.

---